Cysteinyl leukotriene receptor expression pattern affects migration of breast cancer cells and survival of breast cancer patients - PubMed (original) (raw)
. 2011 Jul 1;129(1):9-22.
doi: 10.1002/ijc.25648. Epub 2010 Nov 9.
Affiliations
- PMID: 20824707
- DOI: 10.1002/ijc.25648
Cysteinyl leukotriene receptor expression pattern affects migration of breast cancer cells and survival of breast cancer patients
Cecilia Magnusson et al. Int J Cancer. 2011.
Abstract
The fact that breast cancer patients with local or distal dissemination exhibit decreased survival, promotes a search for novel mechanisms to suppress such tumor progression. Here, we have determined the expression of proinflammatory cysteinyl leukotriene receptors (CysLTRs) in breast tumor tissue and their signaling effect on breast cancer cell functions related to tumor progression. Patients with breast tumors characterized by high CysLT(1)R and low CysLT(2)R expression levels exhibited increased risk of cancer-induced death in univariate analysis for both the total patient group (hazard ratio [HR] = 2.88, 95% confidence interval [CI] = 1.11-7.41), as well as patients with large (>20 mm) tumors (HR = 5.08, 95% CI = 1.39-18.5). Multivariate analysis revealed that patients with large tumors exhibiting high CysLT(1)R and low CysLT(2)R expression levels had a significantly reduced survival, also when adjusted for established prognostic parameters (HR = 7.51, 95% CI = 1.83-30.8). In patients with large (>20 mm) tumors, elevated CysLT(2)R expression predicted an improved 5-year survival (log-rank test p = 0.04). Surprisingly, for longer time periods, this prognostic value was lost. This disappearance coincided with the termination of hormonal treatment. Tamoxifen preserved and even induced transcription of CysLT(2)R, but not CysLT(1)R, in estrogene receptor-positive MCF-7 breast cancer cells. This elevated CysLT(2)R expression decreased, even below the level of untreated cells, when tamoxifen was withdrawn. CysLT(2)R signaling reduced MCF-7 cell migration, but had no effect on either proliferation or apoptosis. Our data indicate that low CysLT(1)R together with high CysLT(2)R expression levels might be useful parameters in prognostication and treatment stratification of breast cancer patients.
Copyright © 2010 UICC.
Similar articles
- Low expression of CysLT1R and high expression of CysLT2R mediate good prognosis in colorectal cancer.
Magnusson C, Mezhybovska M, Lörinc E, Fernebro E, Nilbert M, Sjölander A. Magnusson C, et al. Eur J Cancer. 2010 Mar;46(4):826-35. doi: 10.1016/j.ejca.2009.12.022. Epub 2010 Jan 18. Eur J Cancer. 2010. PMID: 20064706 - Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients.
Holm C, Rayala S, Jirström K, Stål O, Kumar R, Landberg G. Holm C, et al. J Natl Cancer Inst. 2006 May 17;98(10):671-80. doi: 10.1093/jnci/djj185. J Natl Cancer Inst. 2006. PMID: 16705121 - Regulation of cysteinyl leukotriene receptor 2 expression--a potential anti-tumor mechanism.
Magnusson C, Bengtsson AM, Liu M, Liu J, Ceder Y, Ehrnström R, Sjölander A. Magnusson C, et al. PLoS One. 2011;6(12):e29060. doi: 10.1371/journal.pone.0029060. Epub 2011 Dec 15. PLoS One. 2011. PMID: 22194989 Free PMC article. - Cysteinyl leukotriene receptors.
Hui Y, Funk CD. Hui Y, et al. Biochem Pharmacol. 2002 Dec 1;64(11):1549-57. doi: 10.1016/s0006-2952(02)01357-6. Biochem Pharmacol. 2002. PMID: 12429344 Review. - [Research advance in cysteinyl leukotriene receptors with brain injury].
Zhang LH, Zho JB, Wang YF. Zhang LH, et al. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2008 May;37(3):315-20. doi: 10.3785/j.issn.1008-9292.2008.03.018. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2008. PMID: 18546539 Review. Chinese.
Cited by
- Potential of Anti-Leukotriene Drugs as New Therapeutic Agents for Inhibiting Cholangiocarcinoma Progression.
Kito Y, Kachi K, Yoshida M, Hori Y, Kato A, Sahashi H, Toyohara T, Kuno K, Adachi A, Urakabe K, Kataoka H. Kito Y, et al. Molecules. 2024 Jul 18;29(14):3379. doi: 10.3390/molecules29143379. Molecules. 2024. PMID: 39064957 Free PMC article. - Chemoprevention of esophageal adenocarcinoma in a rat surgical model by a cysteinyl leukotriene receptor‑1 antagonist.
Kohno T, Kinoshita J, Oyama K, Saito H, Shimada M, Tsuji T, Yamamoto D, Moriyama H, Inaki N, Ohta T. Kohno T, et al. Oncol Lett. 2024 Feb 8;27(4):147. doi: 10.3892/ol.2024.14280. eCollection 2024 Apr. Oncol Lett. 2024. PMID: 38385106 Free PMC article. - 1,4-dihydroxy quininib activates ferroptosis pathways in metastatic uveal melanoma and reveals a novel prognostic biomarker signature.
Tonelotto V, Costa-Garcia M, O'Reilly E, Smith KF, Slater K, Dillon ET, Pendino M, Higgins C, Sist P, Bosch R, Passamonti S, Piulats JM, Villanueva A, Tramer F, Vanella L, Carey M, Kennedy BN. Tonelotto V, et al. Cell Death Discov. 2024 Feb 10;10(1):70. doi: 10.1038/s41420-023-01773-8. Cell Death Discov. 2024. PMID: 38341410 Free PMC article. - The tumor promoter cysteinyl leukotriene receptor 1 regulates PD-L1 expression in colon cancer cells via the Wnt/β-catenin signaling axis.
Satapathy SR, Ghatak S, Sjölander A. Satapathy SR, et al. Cell Commun Signal. 2023 Jun 14;21(1):138. doi: 10.1186/s12964-023-01157-6. Cell Commun Signal. 2023. PMID: 37316937 Free PMC article. - Altered Expression of CYSLTR1 is Associated With Adverse Clinical Outcome in Triple Negative Breast Tumors: An In Silico Approach.
Céspedes AG, Conceição MPF, de Bastos DR, de Grazia GÁ, Leite JMRS, do Nascimento RG, Ferreira MT, Lopez RM. Céspedes AG, et al. Eur J Breast Health. 2023 Apr 1;19(2):148-158. doi: 10.4274/ejbh.galenos.2023.2022-12-10. eCollection 2023 Apr. Eur J Breast Health. 2023. PMID: 37025579 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical